Michael Gelband’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Michael Gelband’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-12,938	Closed	-$252K	–	2253
2023 Q2	$252K	Buy	+12,938	New	+$307K	﹤0.01%	1613
2023 Q1	–	Sell	-20,199	Closed	-$590K	–	2205
2022 Q4	$590K	Buy	+20,199	New	+$642K	0.01%	1115
2022 Q3	–	Sell	-37,111	Closed	-$1.65M	–	2398
2022 Q2	$1.65M	Buy	+37,111	New	+$1.7M	0.02%	868
2021 Q2	–	Sell	-16,554	Closed	-$691K	–	2917
2021 Q1	$691K	Buy	16,554 +9,059	+121%	+$421K	0.01%	1140
2020 Q4	$349K	Buy	+7,495	New	+$351K	﹤0.01%	1455

Other funds holding EGRX

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Michael Gelband's EGRX Position: Q3 2023 in Review

Michael Gelband sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 12,938 shares — an estimated $252K sold.

Michael Gelband first reported a position in EGRX in Q4 2020 and held it in 5 quarters. The position peaked at $1.65M in Q2 2022. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.

Michael Gelband reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Michael Gelband sold 12,938 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $252K.
Michael Gelband first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2020 and held it in 5 quarters.
Michael Gelband's Eagle Pharmaceuticals, Inc. position peaked at $1.65M in Q2 2022.
107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.

Based on ExodusPoint Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.